je.st
news
Tag: drug
Implant Sciences' Explosives and Drug Trace Detectors Approved for Use in Russia
2015-01-19 11:30:51| Industrial Newsroom - All News for Today
Company's products receive Customs Union Declaration of Conformity Certification and an ETD regulatory approval for the QS-B220 for transportation WILMINGTON, Mass. Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced...
Tags: in
approved
drug
sciences
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia
2015-01-18 02:02:31| Biotech - Topix.net
Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration for the treatment of congenital adrenal hyperplasia a disease that affects approximately 20,000-30,000 people in the United States. "We are very pleased that the FDA has granted NBI-77860 orphan status to treat congenital adrenal hyperplasia, a devastating disease that is a significant challenge for both clinicians and patients," said Malcolm Lloyd-Smith, Chief Regulatory Officer of Neurocrine Biosciences.
Tags: status
treatment
drug
grants
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
2015-01-14 09:33:23| Biotech - Topix.net
New peer-reviewed scientific data from Rexahn is testimony to sound evidence of tumor shrinkage versus popular but problematic Gemzar. Risks include early data that may not translate in larger study results, possible funding needs, regulatory hurdles, and competition for more well-capitalized players.
J&J in deal to develop microbiome drug for bowel diseases
2015-01-13 15:23:06| Food - Topix.net
Johnson & Johnson on Tuesday announced a licensing deal with Vedanta Biosciences to develop the privately held company's lead microbiome-based drug candidate for inflammatory bowel disorders, such as Crohn's disease and ulcerative colitis. J&J said Vedanta will receive an undisclosed upfront payment and would be eligible to receive up to $241 million for achieving development and commercial milestones.
Tags: deal
develop
drug
diseases
Johnson & Johnson licenses Vedanta's bowel disease drug
2015-01-13 15:05:06| Biotech - Topix.net
Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body. J&J's Janssen Pharmaceutical Companies unit says Vedanta Biosciences of Boston could receive up to $241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel disease such as ulcerative colitis or Crohn's disease.
Tags: drug
disease
johnson
licenses
Sites : [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] next »